Dronabinol for Chemotherapy Nausea: Where It Fits Among Anti-Nausea Options | Research

The takeaway

A review of dronabinol's role in chemotherapy-induced nausea and vomiting found it is most useful as an add-on therapy when standard antiemetics fail, with evidence supporting use as monotherapy or combined with ondansetron or prochlorperazine.

Read this if you are undergoing chemotherapy and standard anti-nausea medications are not fully controlling your symptoms.

Dronabinol: valuable rescue option for refractory chemotherapy nausea

What the researchers found

Chemotherapy-induced nausea and vomiting (CINV) is one of patients' most feared side effects. While first-line treatments (corticosteroids, serotonin receptor antagonists, neurokinin antagonists) are effective for many patients, some continue to experience refractory nausea.

This review examined dronabinol's role in this treatment landscape. As a synthetic form of THC, dronabinol has been used for CINV since the 1980s. The review analyzed evidence for three use patterns: as monotherapy, combined with ondansetron (a serotonin antagonist), and combined with prochlorperazine (a dopamine antagonist).

Dronabinol showed lower efficacy than first-line agents and more adverse effects (drowsiness, dizziness, dysphoria). However, it provides a valuable option for patients who fail standard treatments, and combination with other antiemetics may improve its benefit-to-risk ratio.

Why it matters

Despite advances in antiemetic therapy, refractory CINV remains a significant problem. Having additional therapeutic options like dronabinol ensures that patients who fail first-line treatments have alternatives.

The numbers in context

Dronabinol has been available for CINV since the 1980s. Lower efficacy than serotonin and neurokinin antagonists. More adverse effects than first-line agents. Evidence supports combination with ondansetron or prochlorperazine.

How the study worked

Narrative review analyzing clinical evidence for dronabinol in CINV as monotherapy and in combination with ondansetron and prochlorperazine.

What this study cannot tell us

Many studies of dronabinol for CINV are older and used methodology that would not meet current standards. Direct comparisons with newer first-line antiemetics are limited. Individual responses vary widely.

How to read the evidence

Narrative review of clinical evidence, including some older studies. Well-established indication but with limitations in the evidence base.

When this study was published

Published in 2016. Dronabinol has been used for CINV for decades, and newer cannabinoid formulations may offer improvements.

The bigger picture

Dronabinol occupies a specific niche in CINV management: not the first choice, but a valuable rescue option. As more chemotherapy regimens emerge, some with novel patterns of nausea, having diverse antiemetic mechanisms remains important.

Questions still open

Would modern cannabis formulations (CBD-enriched, different THC:CBD ratios) perform differently than dronabinol for CINV? Is dronabinol more effective for certain types of chemotherapy-induced nausea? Would lower doses with fewer side effects maintain antiemetic efficacy?

Common questions

Is dronabinol effective for chemotherapy nausea?

It is less effective and has more side effects than first-line antiemetics, but it provides a valuable option for patients whose nausea does not respond to standard treatments, especially when combined with other anti-nausea drugs.

What are the side effects of dronabinol for nausea?

Common side effects include drowsiness, dizziness, and dysphoria (feeling of unease). These are more frequent than with first-line antiemetics but may be acceptable for patients with otherwise uncontrollable nausea.

Read the original research

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.

Cancer management and research, 8, 49-55

View on PubMed ↗Publisher’s paper ↗

Citation

May, Megan Brafford; Glode, Ashley E. (2016). Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.. Cancer management and research, 8, 49-55. https://doi.org/10.2147/CMAR.S81425